Occlutech AFR Heart Failure Device Obtains CE Mark Approval - 06 September 2019 21:08

SCHAFFHAUSEN, Switzerland, Sept. 6, 2019 /PRNewswire-AsiaNet / -- Occlutech AG announced today that its atrial flow regulator, the Occlutech AFR device, has obtained CE mark approval clearing it for sales on the European CE regulated market. Occlutech AFR is a next generation intra-atrial shunt device, intended ...

  FDI World Dental Federation and Smile Train Launch Project to ... - 06 September 2019 16:00

GENEVA, September 6, 2019, /PRNewswire-AsiaNet/-- - Cleft lip and palate (clefts) are the most common birth difference of the face and mouth. - Clefts happen when certain body parts and structures do not fuse together during fetal development and impact the development of the mouth, gums, and p...

  New FDI World Dental Federation Care Pathway Promotes Dentist-... - 05 September 2019 16:00

SAN FRANCISCO, Sept. 5, 2019 /PRNewswire-AsiaNet/ -- Today during the ADA FDI World Dental Congress in San Francisco, USA, FDI World Dental Federation (FDI) released its latest resources on the treatment and care of patients with partial tooth loss. Rather than losing all their teeth as they age,...

  Spectrum Therapeutics Australia Launches First Tga Registered ... - 05 September 2019 08:00

VICTORIA, Australia, 5 September 2019 /PRNewswire-AsiaNet/ -- Spectrum Therapeutics Australia (Spectrum), the medical division of Canopy Growth Corporation Australia (Canopy Growth), is pleased to announce that the Therapeutic Goods Administration (TGA) has approved the registration of its Storz & Bickel Gmb...

  CROMSOURCE Continues US Growth With New Office in Research Tri... - 04 September 2019 23:00

CARY, North Carolina Sept. 4, 2019 /PRNewswire-AsiaNet/ -- CROMSOURCE, an international contract research organization (CRO) has just opened a newly expanded office in Cary, NC. Due to the growth of CROMSOURCE in the United States over the past few years, this new location serves as a complement to two ex...

  Porsolt Increases Its Drug Discovery Service Capabilities With... - 04 September 2019 02:27

LAVAL, France, Sept. 4, 2019 /PRNewswire-AsiaNet/ -- Porsolt SAS, a long established preclinical screening, efficacy, and safety CRO, has completed a significant expansion of its research facility, adding a further 5,500 sq.ft. of experimental space. The expansion integrates Porsolt's new areas ...

  Polpharma Biologics Announces Global Commercialization Deal fo... - 03 September 2019 16:15

GDANSK, Poland, Sept. 3, 2019 /PRNewswire-AsiaNet/ -- Polpharma Biologics S.A. ("Polpharma Biologics") today announces that it has entered a global commercialization agreement with Sandoz AG for a natalizumab biosimilar. The medicine is currently in Phase III clinical development for the treatment of...

  The First Asia Pacific Psychiatry Symposium Takes Place - 03 September 2019 16:07

NANJING, China, Sept. 3, 2019 /PRNewswire-AsiaNet/ -- - Developments in the Frontiers of Diagnosis and Treatment for Bipolar Disorder and Schizophrenia Receive Extensive Attention The first-ever Asia Pacific Psychiatric Conference hosted by the Luye Pharma Group recently took place in Nanjing. Doz...

  Strekin AG Secures Financing to Complete Development of STR001... - 03 September 2019 16:00

BASEL, Switzerland, Sept. 3, 2019 /PRNewswire-AsiaNet/ -- Strekin AG (www.strekin.com), a clinical stage biopharmaceutical company, announced today that it has successfully closed a Series A financing round totaling CHF 2.82 Million from private investors. These funds will enable Strekin to conclude its ...

  International Atherosclerosis Society & Residual Risk Reductio... - 03 September 2019 03:00

MILAN and BASEL, Switzerland Sept. 3, 2019 AsiaNet /PRNewswire/ -- A new highly selective treatment, a peroxisome proliferator-activated receptor alpha modulator (SPPARM-alpha) agonist, may help to address the gap in managing the residual risk of heart attacks and strokes in high-risk patients, according to over ...